PubMed Health⌕ Search

Biomedical subjects

J Shankleman

Publications and source records attributed to J Shankleman.

3 recordsLinked to original sources

The health of children in refuges for women victims of domestic violence: cross sectional descriptive survey.

OBJECTIVES: To describe the health and developmental status of children living in refugees for women victims of domestic violence and to investigate their access to primary healthcare services. DESIGN: Cross sectional survey. SETTING: Women's refugees in Cardiff. PARTICIPANTS: 148 resident children aged under 16 years and their mothers. MAIN OUTCOME MEASURES: Completeness of records on the child health system (register of all children that includes data on the child's health) for named health visitor, named general practitioner, and immunisation uptake; satisfactory completion of child health surveillance; Denver test results for developmental status; Rutter test scores for behavioural and emotional problems; reports of maternal concerns. RESULTS: 148/257 (58%) children living in refugee between April 1999 and January 2000 were assessed. Child health system data were incorrect (general practitioner and/or address) or unavailable for 85/148 (57%) children. Uptake of all assessments and immunisations was low. 13/68 (19%) children aged <5 years had delayed or questionable development on the Denver test, and 49/101 (49%) children aged 3-15 years had a Rutter score of >10 (indicating probable mental health problems). Concerns were expressed by mothers of 113/148 (76%) children. After leaving the refuge, 22 children were untraceable and 36 returned home to the perpetrator from whom the families had fled. CONCLUSIONS: The children had a high level of need, as well as poor access to services. Time spent in a refuge provides a window of opportunity to review health and developmental status. Specialist health visitors could facilitate and provide support, liaison, and follow up.

Adolescent↗

A comparison of metered dose inhalers with nebulizers from the delivery of ipratropium bromide in domiciliary practice.

In a randomized, double-blind, crossover study consisting of three 1-month periods, we compared the effects of ipratropium bromide (IB) 120 micrograms delivered by a metered dose inhaler (MDI) against two different doses of IB (125 micrograms and 500 micrograms) delivered by a gas driven nebulizer. Thirty-two patients (mean age 57.1 years, range 17-78) with severe airflow obstruction (mean PEFR 192 litres/min, range 75-380 litres/min) were recruited to the study. They had a maximum documented reversibility of over 20% (mean 55.2, range 25-200), and an improvement of over 13% (mean 26.3, range 13-56) in the PEFR to a test dose of 120 micrograms IB delivered by a MDI. In the 20 patients who completed the trial no significant differences were found between the treatment periods when comparisons were made of the weekly averages for the morning PEFR, evening PEFR, reversibility, diurnal variation of the PEFR, bronchodilator and steroid usage. The monthly assessments of FEV1, FVC, VC, RV/TLC ratio and the single breath transfer factor showed all three treatments to be better than the base-line assessment (P less than 0.001), but overall there was no significant difference between treatments. The 6-minute walking distance did not show any improvement over the base-line values with any of the treatments. Symptom scores also showed no overall difference between treatments except for cough which was worse on the 500 micrograms nebulizer solution (P less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗